Objectives To analyse and compare the prognostic factors of breast cancer in the target population of our community-screening programme as a function of the method of detection and to analyse the differences in the prognostic factors as a function of the patient's age and the screening episode. Setting A Breast Cancer-Screening Programme (BCSP) in Northeast Spain. Methods Observational study of all primary malignant breast lesions diagnosed in a woman between 50 and 69 years of age between 18 October 1995 and 31 December 2002. The 16 centres that women from the target population might have attended were contacted. Results A total of 225 (37.2%) of the lesions included were diagnosed through the BCSP, 59 (9.7%) interval cancers were detected, and 321 (53.1%) were detected through other circuits. Node involvement was significantly lower in the lesions detected at screening (32%) in comparison to the interval cancers (41.8%) and those detected through other circuits (47.5%). A significantly larger percentage of the interval tumours (28.6%) and the lesions diagnosed outside the BCSP (22.1%) scored >5.4 on the Nottingham Prognostic Index (NPI) than those diagnosed within the programme (10.9%). The relation between the NPI and the detection method was only statistically significant in the 65-69-year-old age group. The NPI score of the tumours detected by the BCSP showed a statistically significant association with age. Conclusion This analysis has shown notable differences in some prognostic factors for breast cancer according to the method of detection. Association between age and the a priori prognosis of the malignant lesions arises.
INTRODUCTION
T he final objective of screening programmes is to bring about a reduction in the mortality of breast cancer. However, the specific mortality of breast cancer is determined by the characteristics of the disease and by therapeutic actions. 1 Recent disputes over the estimations of the expected reduction in breast cancer mortality through the implementation of screening programmes in Europe underline the appropriateness and difficulties of estimating and separating the benefits of screening from those derived from improved treatments. [2] [3] [4] On the other hand, any possible reduction in mortality due to screening would not be evident for quite a considerable number of years after implementation of the programme. For this reason, the benefits of a screening programme should be evaluated using other, intermediate indicators related to prognostic factors of breast cancer.
Among these prognostic factors, larger tumour size at diagnosis, greater number of lymph nodes with metastases, and worse histological grade have consistently showed a statistically significant association with lower survival and lower disease-free survival. 5 On the other hand, some of these factors are likely to influence decisions about treatment options. Several European authors have evaluated the distribution of the factors having the greatest impact on the prognosis of malignant breast lesions detected in the context of screening programmes and compared it with those detected outside of screening programmes in order to estimate the potential benefit of early detection. 2, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Although it is evident that malignant lesions detected through screening have better prognosis than those identified outside of screening programmes, it is necessary to identify the factors involved and to determine the magnitude of the possible improvements in prognosis.
For all of these reasons, our objectives were to: (1) analyse and compare the prognostic factors of breast cancer in the target population of our community-screening programme as a function of the method of detection; and (2) analyse the differences in the prognostic factors as a function of the patient's age and the screening episode.
METHODS
municipalities covered by the BCSP were included in the study. Therefore, lesions diagnosed in women residing outside the Programme's reference area, relapses of breast cancer, lesions diagnosed in women under 50 or above 69 years and cases in which suspicious lesions proved to be benign were excluded.
Classification of breast lesions
Lesions were classified into three mutually exclusive categories as a function of the detection method: (1) Screening: diagnosed through the woman's participation in the BCSP; (2) Interval neoplasm: diagnosed in women participating in the programme after normal findings on the most recent screening and before the follow-up screening recommended by the programme; and (3) Other: diagnosed through other circuits.
Sources of information and variables
In order to identify all of the lesions, the 16 (public and private) centres in the metropolitan area of Barcelona that might have been attended by women from the target population were contacted. The study protocol, which specified the measures undertaken to ensure confidentiality, was approved by the respective Clinical Research Ethics Committees.
Several different registers were consulted to locate all the women with breast cancer:
(1) the digitized register of all of the patients' visits at the Corporació Sanitaria Parc Tauli-CPT, the reference centre in which all outpatient visits and hospital admissions as well as the findings of imaging, laboratory, and pathology studies are recorded; (2) the BCSP's information system, where all malignancies diagnosed as a consequence of a woman's participation in the programme are recorded, as well as those diagnosed outside of the programme, whether by notification from the woman herself or identified through monthly consultation of the Pathology Register at the reference centre; (3) the Breast Pathology Register of the CPT, where all breast lesions diagnosed at the centre since 1990 are recorded; (4) the Basic Minimum Data Set for Hospital Discharges Register, which contains the diagnoses and procedures codified according to the ICD-9-CM, 21 date of birth and gender, the code for the municipality of residence, the dates of admission and discharge, and the destination at each discharge; (5) specific registers located at the centres contacted: tumour registers or others.
These registers were checked against one another by means of clinical history (CH) numbers or using first names and family names together with date of birth to identify the women diagnosed in the study period to ensure all cases were identified without repetitions. The sensibility of the study in identifying the breast cancer patients was estimated to be 97%, based on the expected number of cases according to the number of discharges with the diagnosis of breast cancer in women 50-69 years living in the BCSP area. 20 The data required for the study were mostly obtained from the documentation present in the CH. Data were collected for the following variables: clinical history number, BCSP code for the woman, date of birth, municipality of residence, date of diagnosis (corresponding to the date of the breast biopsy confirming malignancy; in cases without biopsy, the first date of clinical diagnosis of breast cancer or the date of confirmation by magnetic resonance imaging registered in the clinical history was recorded), method of detection (screening, interval, or other), screening episode (prevalent, incident), symptoms or signs present before diagnosis (in prevalent screening), laterality, maximum diameter of the invasive component of the lesion in mm (p9, 10-14, 15-19, 20-29, 30-49, X50 ; in cases with chemotherapy prior to surgery, the size of the residual lesion was registered, pT (following the World Health Organization [WHO] criteria 22 and those of the International Union against Cancer [IUAC]; 23 in cases without surgery or with prior chemotherapy, the clinical T was recorded), number of lymph nodes affected (1 ¼ none; 2 ¼ 1-3 positive lymph nodes; 3 ¼ X3 axillary lymph nodes affected or pN2 or pN3. If the number of lymph nodes affected was unknown but pN was 1, the lesion was assigned to category 2; in cases with chemotherapy prior to surgery identified after chemotherapy, the number of nodes involved after surgery were recorded), pN (following the WHO and IUAC criteria; in cases without surgery or with chemotherapy prior to surgery, the clinical estimate at the time of diagnosis was recorded), the presence of dissemination of disease (from the TNM at the time of diagnosis and following the IUAC criteria), clinical stage, histological grade according to the Elston criteria, 24 nuclear grade, vessel invasion (only in cases without lymph node involvement), histologic type (according to the WHO criteria), hormone receptor status determined by immunohistochemical techniques, and whether the patient underwent chemotherapy prior to surgery were recorded.
The following variables were generated from the abovementioned recorded variables: age and age group at the time of diagnosis, Nottingham Prognostic Index (NPI) of invasive tumours (0.2 Â tumour size [cm] þ histologic grade [1] [2] [3] þ lymph nodes infiltrated [1] [2] [3] ) and posterior categorization of the NPI 25 4] ). In cases in which the NPI could not be calculated due to the absence of one of the variables comprising it, the NPI was calculated using the values for the variables available and assigning the minimum value for the variables that were missing in order to identify tumours which would clearly belong to a certain category regardless of the unknown values of the missing variables. This enabled some tumours without NPI estimates to be classified in the corresponding categories. Tumours were also classified according to screening exposure status: exposed, if woman attended her last scheduled screening appointment (screendetected and interval cancers) and unexposed, if woman did not attend (including those women who might have attended previous screening rounds, but missed the last screening) or was not yet invited.
Statistical analysis
The unit of analysis was the breast lesion or tumour. The following analyses were carried out: (1) Descriptive and bivariate analyses of the prognostic factors for invasive lesions as a function of the detection method (screening, other, interval), as a function of the exposure status, and for all lesions diagnosed through the BCSP as a function of the screening episode (incident or prevalent). Statistical tests for qualitative measurements (w 2 or Fisher's exact test) were applied. Odds ratios (OR) and corresponding confidence intervals were also calculated for the analysis of the detection method. (2) Stratified analysis of the NPI of invasive tumours by patient age as a function of the detection method or screening episode, applying Fischer's exact test for each stratum.
A 5% a risk for bilateral tests was assumed for all estimations. All analyses were performed using SPSS 11.0 for windows and Stata 8.0.
RESULTS
In the period studied, from 18 October 1995 to 31 December 2002, 679 possible malignant breast lesions were identified. Of these, 74 were excluded and 605 primary malignant breast lesions in 588 different women were finally included. A total of 225 (37.2%) of the lesions included were diagnosed through the BCSP, 59 (9.7%) interval cancers were detected, and 321 (53.1%) were detected through other circuits.
A total of 72 (12%) lesions were classified as in situ, 531 (87.8%) as invasive lesions, and two could not be classified. The percentage of in situ lesions was 5.2% (3) in interval tumours, 18.8% (42) in those detected by the BCSP and 8.6% (27) in the others. A total of 48.3% (292 lesions) were diagnosed in the early stages (0 or I). The proportion of lesions detected in the early stages with respect to those diagnosed in advanced stages (II-IV) was greater after 1999: from that time onward, the percentage of lesions in the early stages was 55-60% (see Figure 1 ).
Prognostic factors of the invasive neoplasms
As shown in Table 1 , more than half of the 531 invasive lesions measured p2 cm (T1). Three-quarters of the malignant lesions detected by screening measured p2 cm and only 5.5% were locally advanced when diagnosed (T4). However, this percentage is 30.9% in interval cancers and 17.8% in the others.
No lymph node involvement was found at the time of diagnosis in 57% of the lesions. This percentage was significantly higher in the lesions detected at screening (68%) in comparison to the interval cancers (58.2%) and those detected through other circuits (52.5%). Likewise, the probability of a tumour diagnosed outside of the programme (interval and others) having ipsilateral lymph node metastases (N2) was significantly higher.
Cancers detected outside the BCSP were twice as likely to involve more than three lymph nodes than were lesions detected at screening. In the BCSP, 57% of the lesions were diagnosed in stage I, while 32-35% of the rest of the lesions were stage I.
A significantly larger percentage of the interval tumours (28.6%) and the lesions diagnosed outside the BCSP (22.1%) scored >5.4 on the NPI, than those diagnosed within the programme (10.9%).
Women with neoplasms exposed to screening had a significantly lower probability of having large tumours or having lymph node involvement, while other biological characteristics, such as histological grade, nuclear grade or hormone receptor status, were similar between the two groups (see Table 2 ).
In the stratified analysis, the relation between the NPI of these invasive tumours and the detection method was only statistically significant in the 65-69-year-old age group (see Table 3 ). In the other age groups, a trend toward better prognosis was also seen in the screening-detected lesions, although this difference did not reach statistical significance.
Prognostic factors of the neoplasms detected through the BCSP
Of the 90 tumours diagnosed in prevalent screening episodes, symptoms and/or signs were present before the mammogram in seven (7.8%).
The tumours diagnosed in incident-screening episodes were smaller, had less lymph node involvement, were slightly more likely to have positive hormone receptors, and had a higher nuclear grade than those diagnosed in prevalent screening (see Table 4 ). However, none of these differences reached statistical significance.
The NPI score of the invasive tumours showed a statistically significant association with age, as shown in Figure 2 . The percentage of lesions with NPI o3.4 was nearly double in women X60 years of age than in those aged 50-59 years. Likewise, the percentage of lesions with NPI>5.4 (worse prognosis) was 19% in the 50-54-year-old age group, 11% in the 55-59-year-old age group and slightly over 10% in the 60-64-year-old age group. In contrast, none of the tumours diagnosed in the 65-69-year-old age group scored above 5.4 on the NPI. Table 3 shows the better a priori prognosis (NPI) in prevalent screening in the 60-64 and 65-69-year-old age groups, although this did not reach statistical significance.
DISCUSSION
The evaluation of mortality poses methodological challenges that, if unresolved, can lead to biased estimates of the effectiveness of a screening programme. [26] [27] Some largescale population-based programmes in Europe have estimated to what extent any reduction in mortality is attributable exclusively to early detection. [28] [29] Unless screening has been underway for many years, the measurement of intermediate outcomes represents a clear alternative for assessing the benefits of a programme for the early detection of breast cancer.
The analysis of prognostic factors for breast cancer has shown that the malignant lesions diagnosed within the framework of the BCSP were smaller and had less lymph node involvement, even when interval and screening cancers are considered together (exposed to screening). Moreover, prevalent screening within the programme has enabled the detection of tumours with more unfavourable prognostic factors. Finally, the application of the NPI has shown a more unfavourable distribution in the youngest age group of the BCSP. Table 1 Continued
Method of detection and breast cancer prognostic factors
These results are congruent with those observed by other authors. [7] [8] [9] 12, 30 In particular, Anderson et al. 15 in the Edinburgh Programme identified 8.7% tumours in situ among those diagnosed through the programme and 2.9% among those diagnosed by other methods (including interval tumours), and these percentages are much lower than those observed in our series. These authors also reported higher percentages of locally advanced tumours and of tumours with dissemination of disease. In 2002 and 2004, Ernst et al. 11, 31 published data from the analysis of invasive tumours diagnosed in women 50-69 years of age registered in the Tumour Registry of Eindhoven, observing statistically significant differences in lymph node involvement and distribution of stages between tumours detected by screening and those detected through other circuits. The better prognosis of tumours diagnosed at screening might be partly attributable to overdiagnosis (i.e. to the detection of lesions that would never have caused symptoms or become life threatening). This matter has been discussed in recent publications. 32, 33 The NPI, which summarizes the main histopathological prognostic factors, is used by European screening programmes to describe their intermediate results. 34 According to this index, for the entire study period the invasive tumours identified outside of the BCSP in this study would be nearly three times more likely to have a poor prognosis (NPI>5.4), and these estimates were even higher in interval tumours. Prior studies found that an NPI score over 5.4 was associated with a 10-year survival rate of 20-25%, in comparison with 60% for moderate NPI scores. [35] [36] On the other hand, the European guidelines for quality assurance in mammography screening recommend that 75-80% of lesions diagnosed in the territories where screening programmes have been implemented should be identified in the early stages. 37 In the programme evaluated in this study, this percentage reached nearly 80% in 2000 (data not shown); however, this percentage then decreased, coinciding with the extension of the programme to new, previously uncovered territories, finally reaching 66.5% in 2002. Amongst the entire population of the BCSP, a predominance of lesions diagnosed in the early stages was first observed in 1999 and became more evident from 2002, when a considerable proportion of the municipalities invited to participate entered the third round. From programmes implemented in Spain there are no population-based data that would allow direct comparison with our results.
With respect to the analysis of the differences in the prognostic factors as a function of screening episode, the second objective of this study, we have observed that tumours diagnosed in prevalent screening have more unfavourable prognoses than those diagnosed in incident screening. Webster et al. 38 recently published an analysis that also found smaller tumour size and less lymph node involvement in incident screening and similar histological grade, and these conclusions are similar to those reported by Erbas et al. 39 These results differ, however, from those published by Holland et al. 40 in 1996, who found the opposite relation in a series of tumours detected between 1993 and 1994. Likewise, Hakama et al. 41 observed that more than 75% of the tumours detected in prevalent screening in three pilot programmes carried out in Finland between 1982 and 1990 were T1-N0, including 16% intraductal or in situ lesions, while those detected through incident screening were similar to interval tumours. Despite the frequency of recent mammograms prior to prevalent screening in our area, 42 which could lead to the inclusion of many tumours that would in fact be incident tumours, the observation that the invasive tumours diagnosed through prevalent screening were larger and had greater lymph node involvement may be related to a longer pre-symptomatic phase and a shorter lead time. 9,43-44 The NPI for the invasive tumours has shown a more unfavourable distribution, especially among women in the 50-54-year-old age group and even in the 55-59-year-old age group. It is noteworthy that the better prognosis for invasive tumours in the 65-69-year-old age group was observed in both prevalent and incident screening, which supports the hypothesis that tumours diagnosed in older women have a better prognosis. With respect to this question, no comparable data have been published, although several authors have observed a more pronounced reduction in mortality in the oldest age groups within the range covered by the BCSP. [45] [46] [47] [48] Tá bar et al. 10 noted in 1999 that breast tumours had a shorter pre-clinical phase in women aged 50-59 years in comparison to women 60-69 years old. However, it is possible that the differences observed in the youngest age group might not begin abruptly at 50 years but rather increase gradually throughout the age group. Michaelson et al. 6 reported smaller tumour size in screening-detected lesions regardless of age, although they also observed that the benefits of early detection might be slightly greater in women aged 60-69 years in comparison to those aged 50-59 years.
Based on the results of our study, which are congruent with those of studies discussed above, and the lack of important differences in the distribution of the NPI with respect to the method of detection in the youngest age group, it is debatable whether biannual screening is the most appropriate periodicity for the youngest age groups considered in European screening programmes. In fact, while some authors have suggested that the benefit of reducing the interval between mammograms is small in women older than 50 years, 49-50 others recommend screening annually or every 18 months for women below 50 years of age and some authors even extend this recommendation to women over 50 years. 51 Without entering into the question of the cost-effectiveness as a function of the interval between mammograms, the results observed suggest that the benefits of biannual screening are not as pronounced in the youngest women in the BCSP.
The contributions of this study to the current body of knowledge about BCSP are: in the first place, this study is one of the few experiences that assess the intermediate results of a service-screening programme from a community perspective; on the other hand, the analysis has shown a possible effect for age in the potential benefits of a programme of this sort, adding to our understanding of the natural history of breast cancer. It is important to bear in mind that the breast cancerscreening programmes in Catalonia, and in Spain in general, follow considerably homogeneous criteria based on the European Guidelines. 37 Consequently, while comparisons among service screening programmes have to be approached with caution, [52] [53] the conclusions of this study can be extrapolated to a large extent to other programmes in Spain and even to the rest of Europe.
In conclusion, this analysis within a breast cancer screening programme in an area without a cancer register for the population has shown notable differences in some prognostic factors for breast cancer according to the method of detection and the exposure status. An improvement in the stages of the malignant lesions in the target population is clearly perceptible at the end of the period assessed. Finally, a possible association between age and the a priori prognosis of the malignant lesions arises. 
